TDRD3

Across TCGA pan-cancer cohorts, TDRD3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TDRD3 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TDRD3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TDRD3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and LUSC are the cancer types where TDRD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	1.000	0.656	.024	6	view →
UCEC	DFS	Median	All	0.890	0.616	.030	4	view →
LUSC	OS	Median	All	0.173	0.724	.046	3	view →
SKCM	DFS	Median	All	0.882	0.614	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TDRD3–LUAD (DFS)

Open the LUAD breakdown →